Suppr超能文献

非agenarians门诊胃肠外抗菌治疗的安全性 (注:这里nonagenarians可能有误,正确的应该是nonagenarian,意为九旬老人,这里按纠正后的翻译为“九旬老人门诊胃肠外抗菌治疗的安全性” )

Safety of Outpatient Parenteral Antimicrobial Therapy in Nonagenarians.

作者信息

Shrestha Nabin K, Blaskewicz Caitlin, Gordon Steven M, Everett Angela, Rehm Susan J

机构信息

Department of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio, USA.

Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA.

出版信息

Open Forum Infect Dis. 2020 Oct 3;7(10):ofaa398. doi: 10.1093/ofid/ofaa398. eCollection 2020 Oct.

Abstract

BACKGROUND

Although widely accepted for adults, the safety of outpatient parenteral antimicrobial therapy (OPAT) in very old patients has not been examined.

METHODS

Nonagenarians (age ≥90 years) discharged from the hospital on OPAT over a 5-year period were identified from the Cleveland Clinic OPAT Registry. Three matched controls (<90 years) were selected for each nonagenarian. Times to OPAT-related emergency department (ED) visit and OPAT-related readmission were compared across the 2 groups in multivariable subdistribution proportional hazards competing risks regression models. Incidence of adverse drug events and vascular access complications were compared using negative binomial regression.

RESULTS

Of 126 nonagenarians and 378 controls, 7 were excluded for various reasons. Among the remaining 497 subjects, 306 (62%) were male, 311 (63%) were treated for cardiovascular or osteoarticular infections, and 363 (73%) were discharged to a residential health care facility. The mean (SD) ages of nonagenarians and controls were 92 (2) and 62 (16) years, respectively. Compared with matched controls, being a nonagenarian was not associated with increased risk of OPAT-related ED visit (hazard ratio [HR], 0.77; 95% CI, 0.33-1.80;  = .55), OPAT-related readmission (HR, 0.78; 95% CI, 0.28-2.16;  = .63), adverse drug event from OPAT medications (incidence rate ratio [IRR], 1.00; 95% CI, 0.43-2.17;  = .99), or vascular access complications (IRR, 0.66; 95% CI, 0.27-1.51;  = .32). Nonagenarians had a higher risk of death overall (HR, 2.64; 95% CI, 1.52-4.58;  < .001), but deaths were not from OPAT complications.

CONCLUSIONS

Compared with younger patients, OPAT in nonagenarians is not associated with higher risk of OPAT-related complications. OPAT can be provided as safely to nonagenarians as to younger patients.

摘要

背景

门诊胃肠外抗菌治疗(OPAT)在成年人中已被广泛接受,但在高龄患者中的安全性尚未得到研究。

方法

从克利夫兰诊所OPAT登记处识别出在5年期间因OPAT出院的90岁及以上老人(年龄≥90岁)。为每位90岁及以上老人选择3名匹配对照(年龄<90岁)。在多变量子分布比例风险竞争风险回归模型中比较两组患者与OPAT相关的急诊就诊时间和与OPAT相关的再入院时间。使用负二项回归比较药物不良事件和血管通路并发症的发生率。

结果

在126名90岁及以上老人和378名对照中,7人因各种原因被排除。在其余497名受试者中,306名(62%)为男性,311名(63%)因心血管或骨关节感染接受治疗,363名(73%)出院后入住住宅保健机构。90岁及以上老人和对照的平均(标准差)年龄分别为92(2)岁和62(16)岁。与匹配对照相比,90岁及以上老人与OPAT相关的急诊就诊风险增加无关(风险比[HR],0.77;95%置信区间,0.33 - 1.80;P = 0.55),与OPAT相关的再入院风险增加无关(HR,0.78;95%置信区间,0.28 - 2.16;P = 0.63),与OPAT药物引起的药物不良事件无关(发生率比[IRR],1.00;95%置信区间,0.43 - 2.17;P = 0.99),也与血管通路并发症无关(IRR,0.66;95%置信区间,0.27 - 1.51;P = 0.32)。90岁及以上老人总体死亡风险较高(HR,2.64;95%置信区间,1.52 - 4.58;P < 0.001),但死亡并非由OPAT并发症导致。

结论

与年轻患者相比,90岁及以上老人接受OPAT与OPAT相关并发症的较高风险无关。90岁及以上老人接受OPAT的安全性与年轻患者相当。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d114/7532659/320215816c4c/ofaa398f0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验